Hyunsoo Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hyunsoo Kim has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Danbee Kang
Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea
14 shared publications - Juhee Cho
Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
11 shared publications - Hye Yun Park
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
5 shared publications - Sun Hye Shin
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea
5 shared publications - Taeyun Kim
Division of Pulmonology, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea
5 shared publications - Byung Joo Chae
Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- 30 September 2026
- Published by Wiley in Respirology
Frailty, Chronological Age, and Clinical Outcomes in COPD : A Nationwide Cohort Study
Background and Objectives: Frailty and chronological age are major prognostic factors in chronic obstructive pulmonary disease (COPD), yet their combined effects have not been fully examined in large population‐based cohorts. We investigated whether low frailty attenuates the adverse impact of aging on COPD outcomes. Methods: We conducted a nationwide retrospective cohort study using the Korean National Health Insurance Service database. Patients aged ≥ 40 years diagnosed with COPD between 2010 and 2021 were included. Frailty was assessed using a claims‐based frailty index and categorized as low, intermediate, or high. The primary outcome was all‐cause mortality, and the secondary outcome was severe exacerbation. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs). Results: Among 1,505,638 patients with COPD, 784,962 were aged < 70 years and 720,676 were aged ≥ 70 years. Over a median follow‐up of 7.0 years (interquartile range, 3.0–10.3), 500,097 deaths and 169,102 severe exacerbations occurred. Compared with older patients (≥ 70 years) with low frailty, intermediate frailty was associated with higher mortality risk in both younger (HR 1.19; 95% CI 1.17–1.21) and older patients (HR 1.21; 95% CI 1.20–1.21). High frailty showed highest risk (HR 2.66; 95% CI 2.54–2.78 in < 70 years; HR 1.90; 95% CI 1.87–1.93 in ≥ 70 years). Similar graded associations were observed for severe exacerbations. Conclusion: In patients with COPD, frailty risk provided prognostic information beyond chronological age, highlighting the importance of biological vulnerability in determining outcomes in COPD.
- 30 September 2026
- Published by Wiley in Respirology
Frailty, Chronological Age, and Clinical Outcomes in COPD : A Nationwide Cohort Study
Background and Objectives: Frailty and chronological age are major prognostic factors in chronic obstructive pulmonary disease (COPD), yet their combined effects have not been fully examined in large population‐based cohorts. We investigated whether low frailty attenuates the adverse impact of aging on COPD outcomes. Methods: We conducted a nationwide retrospective cohort study using the Korean National Health Insurance Service database. Patients aged ≥ 40 years diagnosed with COPD between 2010 and 2021 were included. Frailty was assessed using a claims‐based frailty index and categorized as low, intermediate, or high. The primary outcome was all‐cause mortality, and the secondary outcome was severe exacerbation. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs). Results: Among 1,505,638 patients with COPD, 784,962 were aged < 70 years and 720,676 were aged ≥ 70 years. Over a median follow‐up of 7.0 years (interquartile range, 3.0–10.3), 500,097 deaths and 169,102 severe exacerbations occurred. Compared with older patients (≥ 70 years) with low frailty, intermediate frailty was associated with higher mortality risk in both younger (HR 1.19; 95% CI 1.17–1.21) and older patients (HR 1.21; 95% CI 1.20–1.21). High frailty showed highest risk (HR 2.66; 95% CI 2.54–2.78 in < 70 years; HR 1.90; 95% CI 1.87–1.93 in ≥ 70 years). Similar graded associations were observed for severe exacerbations. Conclusion: In patients with COPD, frailty risk provided prognostic information beyond chronological age, highlighting the importance of biological vulnerability in determining outcomes in COPD.
- Open Access
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Short-Term Impact of Fine Particulate Matter on Hepatic Decompensation in Cirrhosis: A Nationwide Case-Crossover Study
Yewan Park, Suna Kang, Jihee Nam, Jin Lee, Hwamin Woo, Hyunsoo Kim, Sung-Won Kang, Juhee Cho, Danbee Kang, Geum-Youn Gwak. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260039
- 19 August 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessShort-Term Impact of Fine Particulate Matter on Hepatic Decompensation in Cirrhosis: A Nationwide Case-Crossover Study
Yewan Park, Suna Kang, Jihee Nam, Jin Lee, Hwamin Woo, Hyunsoo Kim, Sung-Won Kang, Juhee Cho, Danbee Kang, Geum-Youn Gwak. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260039
- Open Access
- 12 February 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
E-cigarette switching in COPD: reduced cardiovascular events without improvement in respiratory outcomes
The impact of switching to e-cigarettes in smokers after a chronic obstructive pulmonary disease (COPD) diagnosis on long-term health outcomes has not been
- 12 February 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessE-cigarette switching in COPD: reduced cardiovascular events without improvement in respiratory outcomes
The impact of switching to e-cigarettes in smokers after a chronic obstructive pulmonary disease (COPD) diagnosis on long-term health outcomes has not been
- Open Access
- 1 January 2026
- Published by XMLink in Clinics in Orthopedic Surgery
- Vol. 18 (5) , 800
Comparison of Mortality and Revision Rates between Cemented and Cementless Fixation in Bipolar Hemiarthroplasty: A Nationwide Cohort Study
Park JW, et al. Clin Orthop Surg. 2026 ;18:e43. https://doi.org/10.4055/cios25301
- 1 January 2026
- Published by XMLink in Clinics in Orthopedic Surgery
- Vol. 18 (5) , 800
Open AccessComparison of Mortality and Revision Rates between Cemented and Cementless Fixation in Bipolar Hemiarthroplasty: A Nationwide Cohort Study
Park JW, et al. Clin Orthop Surg. 2026 ;18:e43. https://doi.org/10.4055/cios25301
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (30)
Cement Use in Bipolar Hemiarthroplasty and Its Association With Cancer Risk
Park JW, et al. J Korean Med Sci. 2026 Aug;41:e196. https://doi.org/10.3346/jkms.2026.41.e196
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (30)
Open AccessCement Use in Bipolar Hemiarthroplasty and Its Association With Cancer Risk
Park JW, et al. J Korean Med Sci. 2026 Aug;41:e196. https://doi.org/10.3346/jkms.2026.41.e196
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
Increased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer
Choi HL, et al. J Gynecol Oncol. 2025 Mar;36:e75. https://doi.org/10.3802/jgo.2025.36.e75
- 1 January 2025
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 36 (5)
Open AccessIncreased cardiovascular disease risk among adolescent and young adult survivors of cervical cancer
Choi HL, et al. J Gynecol Oncol. 2025 Mar;36:e75. https://doi.org/10.3802/jgo.2025.36.e75
- Open Access
- 2 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Association of moderate-to-vigorous physical activity with reduction of acute exacerbation in COPD patients using a dual ultra-long-acting bronchodilators
Inhaler therapy and physical activity (PA) are important methods of chronic obstructive pulmonary disease (COPD) management. This study aimed to investigate the additional benefit of moderate-to-vigorous PA (MVPA) in patients with COPD using a long-acting beta-agonists (LABA)/long-acting muscarinic antagonist (LAMA) combination. We emulated a target trial to estimate the benefit of MVPA in patients with COPD using a dual ultra-long-acting bronchodilators. We enrolled patients aged ≥ 40 who were diagnosed with COPD between 2014 and 2018, initiated a LABA/LAMA combination, and had not undergone regular MVPA. The main exposure was the initiation of MVPA, defined as vigorous aerobic exercise > 20 min per day on ≥ 3 days/week or moderate aerobic exercise > 30 min per day on ≥ 5 days/week. The main outcomes were the future usage of inhaled corticosteroids (ICS) and severe exacerbation. We identified 1,526 patients who initiated MVPA and 4,516 who did not. The median follow-up period was 3.0 years. The hazard ratio (HR) for future ICS usage in the MVPA initiation group was 0.83 (95% confidence intervals (CI): 0.72, 0.97) compared to the control group. The HR for severe exacerbation in the MVPA initiation group was 0.81 (95% CI: 0.68, 0.96) compared to the control group. Subgroup analyses by age, sex, body mass index, residence area, smoking and drinking status showed consistent benefits in these outcomes. Initiation of MVPA may offer an additional benefit for even COPD patients who use a dual ultra-long-acting bronchodilators.
- 2 November 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessAssociation of moderate-to-vigorous physical activity with reduction of acute exacerbation in COPD patients using a dual ultra-long-acting bronchodilators
Inhaler therapy and physical activity (PA) are important methods of chronic obstructive pulmonary disease (COPD) management. This study aimed to investigate the additional benefit of moderate-to-vigorous PA (MVPA) in patients with COPD using a long-acting beta-agonists (LABA)/long-acting muscarinic antagonist (LAMA) combination. We emulated a target trial to estimate the benefit of MVPA in patients with COPD using a dual ultra-long-acting bronchodilators. We enrolled patients aged ≥ 40 who were diagnosed with COPD between 2014 and 2018, initiated a LABA/LAMA combination, and had not undergone regular MVPA. The main exposure was the initiation of MVPA, defined as vigorous aerobic exercise > 20 min per day on ≥ 3 days/week or moderate aerobic exercise > 30 min per day on ≥ 5 days/week. The main outcomes were the future usage of inhaled corticosteroids (ICS) and severe exacerbation. We identified 1,526 patients who initiated MVPA and 4,516 who did not. The median follow-up period was 3.0 years. The hazard ratio (HR) for future ICS usage in the MVPA initiation group was 0.83 (95% confidence intervals (CI): 0.72, 0.97) compared to the control group. The HR for severe exacerbation in the MVPA initiation group was 0.81 (95% CI: 0.68, 0.96) compared to the control group. Subgroup analyses by age, sex, body mass index, residence area, smoking and drinking status showed consistent benefits in these outcomes. Initiation of MVPA may offer an additional benefit for even COPD patients who use a dual ultra-long-acting bronchodilators.
- Open Access
- 30 March 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-10
Longitudinal BMI change and outcomes in Chronic Obstructive Pulmonary Disease: a nationwide population-based cohort study
Background: The association between longitudinal body mass index (BMI) change and clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) has not fully investigated. Methods: This retrospective cohort study included 116,463 COPD patients aged ≥ 40, with at least two health examinations, one within 2 years before and another within 3 years after COPD diagnosis (January 1, 2014, to December 31, 2019). Associations between BMI percentage change with all-cause mortality, primary endpoint, and initial severe exacerbation were assessed. Results: BMI decreased > 5% in 14,728 (12.6%), while maintained in 80,689 (69.2%), and increased > 5% in 21,046 (18.1%) after COPD diagnosis. Compared to maintenance group, adjusted hazard ratio (aHR) for all-cause mortality was 1.70 in BMI decrease group (95% CI:1.61, 1.79) and 1.13 in BMI increase group (95% CI:1.07, 1.20). In subgroup analysis, decrease in BMI showed a stronger effect on mortality as baseline BMI was lower, while an increase in BMI was related to an increase in mortality only in obese COPD patients with aHRs of 1.18 (95% CI: 1.03, 1.36). The aHRs for the risk of severe exacerbation (BMI decrease group and increase group vs. maintenance group) were 1.30 (95% CI:1.24, 1.35) and 1.12 (95% CI:1.07, 1.16), respectively. Conclusions: A decrease in BMI was associated with an increased risk of all-cause mortality in a dose-dependent manner in patients with COPD. This was most significant in underweight patients. Regular monitoring for weight loss might be an important component for COPD management.
- 30 March 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-10
Open AccessLongitudinal BMI change and outcomes in Chronic Obstructive Pulmonary Disease: a nationwide population-based cohort study
Background: The association between longitudinal body mass index (BMI) change and clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) has not fully investigated. Methods: This retrospective cohort study included 116,463 COPD patients aged ≥ 40, with at least two health examinations, one within 2 years before and another within 3 years after COPD diagnosis (January 1, 2014, to December 31, 2019). Associations between BMI percentage change with all-cause mortality, primary endpoint, and initial severe exacerbation were assessed. Results: BMI decreased > 5% in 14,728 (12.6%), while maintained in 80,689 (69.2%), and increased > 5% in 21,046 (18.1%) after COPD diagnosis. Compared to maintenance group, adjusted hazard ratio (aHR) for all-cause mortality was 1.70 in BMI decrease group (95% CI:1.61, 1.79) and 1.13 in BMI increase group (95% CI:1.07, 1.20). In subgroup analysis, decrease in BMI showed a stronger effect on mortality as baseline BMI was lower, while an increase in BMI was related to an increase in mortality only in obese COPD patients with aHRs of 1.18 (95% CI: 1.03, 1.36). The aHRs for the risk of severe exacerbation (BMI decrease group and increase group vs. maintenance group) were 1.30 (95% CI:1.24, 1.35) and 1.12 (95% CI:1.07, 1.16), respectively. Conclusions: A decrease in BMI was associated with an increased risk of all-cause mortality in a dose-dependent manner in patients with COPD. This was most significant in underweight patients. Regular monitoring for weight loss might be an important component for COPD management.
- Open Access
- 18 March 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-11
Impact of smoking reduction on lung cancer risk in patients with COPD who smoked fewer than 30 pack-years: a nationwide population-based cohort study
Background: The effects of smoking reduction on the incidence of lung cancer in patients with chronic obstructive pulmonary disease (COPD) are not well known. This study aimed to investigate the effects of changes in smoking habits after COPD diagnosis on lung cancer development in patients who smoked less than 30 pack-years. Methods: This nationwide retrospective cohort study included 16,832 patients with COPD who smoked less than 30 pack-years at the time of COPD diagnosis. Based on changes in smoking habits in the health screening examination data, smokers were categorized into three groups: quitters, reducers, and sustainers. The primary outcome was the risk of lung cancer development, which was estimated using the Cox proportional hazards model. We also modelled the amount of smoking reduction as a continuous variable. Results: During a median follow-up of 4 years, the cumulative incidence of lung cancer was the highest among sustainers, followed by reducers and quitters. Compared with sustainers, reducers (adjusted HR 0.74, 95% CI:0.56–0.98) and quitters (adjusted HR 0.78, 95% CI:0.64–0.96) had a significantly lower risk of lung cancer. Incidence of lung cancer showed a decreasing trend with a decreasing amount of smoking (P for linearity < 0.01). Conclusions: In patients with COPD who smoked less than 30 pack-years, smoking reduction and cessation lowered the risk of lung cancer.
- 18 March 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-11
Open AccessImpact of smoking reduction on lung cancer risk in patients with COPD who smoked fewer than 30 pack-years: a nationwide population-based cohort study
Background: The effects of smoking reduction on the incidence of lung cancer in patients with chronic obstructive pulmonary disease (COPD) are not well known. This study aimed to investigate the effects of changes in smoking habits after COPD diagnosis on lung cancer development in patients who smoked less than 30 pack-years. Methods: This nationwide retrospective cohort study included 16,832 patients with COPD who smoked less than 30 pack-years at the time of COPD diagnosis. Based on changes in smoking habits in the health screening examination data, smokers were categorized into three groups: quitters, reducers, and sustainers. The primary outcome was the risk of lung cancer development, which was estimated using the Cox proportional hazards model. We also modelled the amount of smoking reduction as a continuous variable. Results: During a median follow-up of 4 years, the cumulative incidence of lung cancer was the highest among sustainers, followed by reducers and quitters. Compared with sustainers, reducers (adjusted HR 0.74, 95% CI:0.56–0.98) and quitters (adjusted HR 0.78, 95% CI:0.64–0.96) had a significantly lower risk of lung cancer. Incidence of lung cancer showed a decreasing trend with a decreasing amount of smoking (P for linearity < 0.01). Conclusions: In patients with COPD who smoked less than 30 pack-years, smoking reduction and cessation lowered the risk of lung cancer.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (24) , e191
Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation
Kim J, et al. J Korean Med Sci. 2024 Jun;39:e191. https://doi.org/10.3346/jkms.2024.39.e191
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (24) , e191
Open AccessOptimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation
Kim J, et al. J Korean Med Sci. 2024 Jun;39:e191. https://doi.org/10.3346/jkms.2024.39.e191